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Abstract: 
 
We report that subunits of human nuclear proteasomes carry a previously unrecognised, 
constitutive posttranslational modification. Subunits with this modification are not visualised by 
SDS-PAGE, which is used in almost all denaturing protein gel electrophoresis. In contrast, CTAB-
PAGE readily visualises such modified subunits. Thus, under most experimental conditions, with 
the identical samples, SDS-PAGE yielded gel electrophoresis patterns for subunits of nuclear 
proteasomes which were misleading and strikingly different from those obtained with CTAB-
PAGE. Initial analysis indicates a novel modification of high negative charge with some similarity 
to polyADP-ribose, possibly explaining compatibility with (positively-charged) CTAB-PAGE but 
not (negatively-charged) SDS-PAGE and providing a mechanism for how nuclear proteasomes 
may interact with chromatin, DNA and other nuclear components. 
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1.1 Introduction 
Most denaturing protein gel electrophoresis is done using SDS-PAGE, discontinuous Sodium 
Dodecyl Sulphate PolyAcrylamide Gel Electrophoresis,[1] due to its ease-of-use and reliability[2]. 
Although some posttranslational modifications may affect the migration behaviour of proteins on 
SDS-PAGE, e.g. N-linked glycosylation, SDS-PAGE is believed to, and generally does, faithfully 
represent the composition of complex protein mixtures[2]. However, we now report a novel 
modification of nuclear proteasomes that prevents SDS-PAGE from visualising the proteasomal 
subunits. By way of further background, proteasomes[3-4] are 2.5 MDa protease complexes, 
located in the cytoplasm and nucleus, which degrade ubiquitin-marked protein substrates. There 
is an alternative to SDS-PAGE, the much less used CTAB(Cetyl Trimethyl Ammonium Bromide)-
PAGE system[5-6]. We report that, unlike SDS-PAGE, CTAB-PAGE does visualise these modified 
subunits of nuclear proteasomes. Thus, for nuclear proteins, combined use of SDS-PAGE and 
CTAB-PAGE may be required to capture sample complexity. Initial analysis into the nature of the 
posttranslational modification indicates that the modification shares several characteristics with, 
but also is distinct from, classical ADP-ribose chains. 
 
2.1 Materials and Methods 
 
2.1.1 Antibodies, Chemicals, Enzymes, Western Blotting, Tissue Culture. List of commercial 
antibodies: Enzo Lifesciences: -Rpn10/S5a (MoAb S5a-18, BML-PW9250), -Rpn12/S14 (PAb, 
BML-PW8815), -20S 7 (MoAb LN43, BML-PW8110), -20S 6 (MoAb MCP20, BML-PW8100), -
Rpt1/S7 (MoAb MSS1-104, BML-PW8825), -Rpt2/S4 (PAb, BML-PW8305), -Rpt3/S6b (PAb, BML-
PW8175), -Rpt4/S10b (MoAb p42-23, PW8830), -Rpt5/S6a (MoAb TBP1-19, PW8770), -‘core’ 
CP subunits (PAb, PW8155), -5i/LMP7 (PAb, PW8355), -ubiquitin (FK2, PW8810), -poly(ADP-
ribose) (PAb 96-10-04, ALX-210-890-R100). -Rpn1/S2: Calbiochem (539166). -Lamin B2: Abcam 
(MoAb, ab8983). -SMARCB1/Ini1: Santa Cruz (PAb, sc-13055). -Ubiquilin1: Invitrogen (MoAb, 
377700). 
Bortezomib: Millennium/Takeda. Epoxomicin, Ada-K(Biot)-Ahx3-L3-VS: Enzo Lifesciences. 
Doxorubicin, vinblastin, cycloheximide, epigallocatechin gallate (EGCG): Sigma-Aldrich. 
Micrococcal nuclease, RNaseA/T1, RNaseH and RNAse1: Fermentas/Thermo. Antibodies against 
yeast proteasome: Dr Daniel Finley, Harvard Medical School. -Dbf11 antibody: Dr Christian Speck, 
CSC-MRC London. We generated -glucanase (O. xanthineolytica) using an E. coli strain gifted by 
Dr Randy Schekman, UC Berkeley. PDE1 (from Crotalus Adamanteus venom): Sigma-Aldrich. PARG, 
ARH3 and ARH1: Enzo Life Sciences (ALX-202-045-UC01, ALX-201-290-C010, ALX-201-293-C010). 
We cloned the two variants of ARH2 into pET23a(+) using a HeLa cDNA library (Gibco). PAR 
enzyme incubations were overnight at 37oC. Extra Ca++ or Mg++ was supplied where necessary. 
Caspase Inhibitor Set III: Enzo, ALX-850-227-KI01, 1:500 dil.=4 M. Antibodies were diluted in 
PBS+0.5% Tween20 for Western blotting, PVDF membranes were re-probed multiple times [7]. 
NCI-H929, KMS12-BM, RPMI-8226, OPM2, DG75 and Jurkat cells were grown in RPMI (Sigma), 
supplemented with 10% v/v FBS, and 1% v/v Pen/strep. SAOS2 and HEK293T cells were grown in 
DMEM (Sigma) with 10% v/v FBS, and 1% v/v Pen/strep. 
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2.1.2 CTAB-PAGE, and isoelectric focusing. CTAB-PAGE as published [6]. In short, 6% resolving gel 
(2.4 ml 40% acrylamide, 4 ml 1.5 M Tricine-NaOH [pH 8.0], 9.4 ml water, 160 μl 10% APS, 16 μl 
TEMED) was used to pour the separating gel. For the stacking gel, 30 mg agarose was mixed with 
1.25 ml 0.5 M Tricine-NaOH [pH 10], 3.7 ml water, and 50 μl 10% CTAB solution (this solution has 
limited shelf life; discard and re-make after one month). The CTAB-PAGE gel was run in CTAB 
running buffer (25 mM Tricine, 13.75 mM CTAB, 75 mM arginine; using 5x stock). Protein samples 
were mixed with equal amount of 2×CTAB sample buffer (10 mM Tricine-NaOH [pH 8.8], 1% w/v 
CTAB, 10% v/v glycerol, 10 μl/ml saturated aqueous solution of crystal violet, 2% v/v -
mercaptoethanol). Samples were heated up at 94:C for 3-4 min, and 20 μl of sample were loaded 
in the wells. CTAB gels were run at 100 Volts, with leads reversed. After clearing the stacking gel, 
voltage was increased to 150V. Proteins were transferred to PVDF membrane using a semi-dry 
transfer system (Biorad: transfer time 20 minutes; set at 15 V, with a limit of 400 mA). Isoelectric 
focusing was done with the IPG-ZOOM system (Invitrogen), using a linear pH3-10 (ZM0018) or 
pH4-7 (ZM0012) gradient immobilized on strip according to manual’s protocol, and followed by a 
second-dimension SDS-PAGE step. 
 
2.1.3 Cell fractionation: cytosolic and nuclear protein extraction. Cytosolic and nuclear protein 
extractions were prepared from approximately 2 × 106 NCI-H929 or KMS12-BM Myeloma cells, 
harvested by centrifugation at 1,500 rpm for 5 min. All steps below were carried out on ice or with 
pre-chilled reagents and equipments. Cell pellets were washed once with 1 ml PBS and harvested 
by centrifugation at 5000xg for 5 min, 4:C. The pellet was resuspended in 110 μl cytosol (C)  
extraction buffer (25 mM Tris-HCl [pH 7.8], 5 mM MgCl2/EDTA, 1 mM ATP/ADP, 2 mM DTT, 150 
mM NaCl, 0.1% NP-40/IGEPAL) by pipetting up and down 20 times, and then spun down at 5000xg 
for 5 min at 4:C. 100 μl of the supernatant (the cytosolic extract: C) was transferred to new 
Eppendorf tubes and mixed with equal amount of 2×SDS/CTAB sample buffer. The remaining 
liquid was discarded. Next, the pellets were re-suspended in 110 μl nuclear extract (NE) buffer[8] 
(20 mM HEPES [pH 7.4], 420 mM NaCl, 0.5 mM EDTA, 0.5 mM EGTA, 1 mM DTT, 1 tablet of 
inhibitor cocktail (Roche) per 50 ml) by pipetting up and down 20 times, and then left on ice for 20 
min. After vortexing 10 seconds, the mixtures were spun down at 10,000xg for 20 min at 4 :C. 100 
μl of the supernants (the nuclear extracts: NE) were transferred to new 1.5-ml microcentrifuge 
tubes and mixed with equal amount of 2×SDS/CTAB sample buffer. The remainder of the 
supernatant was discarded. Next, 110 μl of nuclear extract buffer was added to the pellets (the 
nuclear pellet fraction: NP), and mixed with equal amount of 2×SDS/CTAB sample buffer. When 
using the NE for enzyme treatment, 2 volumes of H2O were added to 1 volume NE to reduce the 
NaCl concentration to physiological levels. 
  
2.1.4 Purification of yeast proteasomes, and of nuclear proteasomes from primary human 
leukocytes or OPM2 myeloma cells. Yeast proteasomes were affinity-purified using strain sMK-50 
as published [9]. C-terminally His6-tagged ubiquitin-like (Ubl) domain of hPLIC2 was used to 
capture human proteasomes (construct #4615, [10]), except for Figures 2A, 2B, S2 and S3 where 
GST-Ubl (construct #4602; [11]) and GST-Uba (construct #4607; [11]) were used. Bacterial 
expression and affinity-purification (Sigma, His Select HF Nickel Affinity Gel, H0537) was described 
previously [10]. Ubl-His6 protein from one litre of bacterial culture was loaded onto 600 μl of resin. 
Human leukocytes from anonymised donor leukophoresis collections (released for research with 
donor consent) were thawed, washed twice in PBS and centrifuged at low speed at 4:C to obtain a 
dry cell pellet which was resuspended in 6 ml of cytosol extraction buffer (25 mM Tris-HCl [7.6], 5 
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mM EDTA, 1 mM ADP, 2 mM DTT, 150 mM NaCl, 0.1% v/v NP40/IGEPAL) by pipetting up/down 
several times, and spun down again at 3,000 rpm for 7 minutes at 4:C in a Beckman J-M6 JA4.2 
rotor). Next, supernatant was removed, and cells were resuspended in 5 ml of nuclear extract 
buffer (see section above) by carefully pipetting several times using a 25-ml volume pipette. The 
suspension was incubated on ice for 20 minutes, then spun down for 20 minutes at 3000 rpm at 
4:C (Beckman J-M6 JA4.2 rotor). Supernatant, i.e. nuclear extract, was recovered and diluted with 
2 volumes of ddH2O. The 600 μl of Ubl-His6-loaded Ni
++NTA resin was added to the diluted nuclear 
extract, and rotated at 4:C for 1 hr. Next, the beads were washed several times in 25 mM Tris-HCl 
[7.6], 1 mM ADP, 2 mM DTT, 100 mM NaCl, 0.1% NP40/IGEPAL, 1 mM EDTA. Ubl-His6 proteins 
carrying captured proteasomes were eluted by incubation with a 75% wash buffer/25% 1M 
imidazole solution. Eluate was concentrated in YM-50 Centricon, and applied to a Superose6 PC-
3.2/30 column. The FPLC running buffer was 25 mM Tris-HCl [7.6], 2 mM DTT, 150 mM NaCl, 0.1% 
NP40/IGEPAL, 5 mM EDTA, 0.1 mM ATP. 100 l fractions were collected, and analysed by both 
CTAB-PAGE and SDS-PAGE. For Figures 1F, 2A, 2B, S2 and S3, the cytosolic extract was also used 
for further proteasome purification steps. For Figures 2A, 2B, S2 and S3, myeloma OPM2 cells 
were used. 
 
3.1 Results and Discussion 
When comparing the same human cell lysate sample side-by-side on SDS-PAGE and CTAB-
PAGE, we noticed unexpected differences in the resulting gels. In more detail: Western Blot 
analysis with a panel of proteasome antibodies showed the expected distinct separate band or 
bands on SDS-PAGE. Unexpectedly, only CTAB-PAGE showed the presence of multiple additional 
high-molecular weight species for individual proteasome subunits (Figure1A). CTAB-PAGE is not 
inherently prone to smearing: (a) CTAB-PAGE performed equally well as SDS-PAGE in separating a 
mixture of defined purified proteins (FigureS1), in line with published reports[5-6]. (b) Our 
standard conditions with β-mercaptoethanol and sample boiling completely denatured multimeric 
protein complexes -amylase and alcohol dehydrogenase into their monomeric subunits with both 
CTAB-PAGE and SDS-PAGE (FigureS1). (c) Not all proteins we looked at migrated on CTAB-PAGE as 
multiple species, e.g. not LaminB2, Ini1, or Rpt3, Figures 1A, 1D. (d) CTAB-PAGE-unique bands 
were not the result of combining CTAB-PAGE with any particular research reagent: we gathered 
and tested a large number of antibodies against different proteasome subunits, and observed 
CTAB-PAGE-unique bands for most of these (Figure1D, 1E). 
 
We predicted that, if CTAB-PAGE-unique bands represented distinct species of proteasome 
subunits, they would persist in isolation on CTAB-PAGE. To test this, we attempted to purify the 
CTAB-PAGE-unique bands away from main-band material in order to run both fractions in separate 
lanes on CTAB-PAGE. We found that, using sub-cellular fractionation[12] (Figure1B-1D), and 
irrespective of cell type used (Figure 1A,1B), CTAB-PAGE-unique material could be separated from 
main-band material and that it persisted in isolation.  Most of the main-band material was NP40-
extractable (cytosolic), whereas the CTAB-PAGE-unique bands were found in the nuclear pellet 
and could be separated further from chromatin and nuclear architecture using a nuclear 
extraction step (Figure1D)[8]. EDTA in the fractionation buffer improved separation of the main 
band from the collection of high-molecular-weight bands, bands which were then stable and 
immune even to prolonged incubation at 37oC (Figure1C). A subsequent high-salt nuclear 
extraction step removed about half of the proteasomes from the nuclear pellet; we used the 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
6 
 
chromatin remodelling complex component SMARCB1/Ini1 as positive control and Lamin B2 as 
negative control (Figure1D). Note that it was not the nuclear environment in which proteasomes 
reside at the moment of encountering CTAB in the lysis buffer that determined their subunits’ 
migration behaviour on CTAB-PAGE: CTAB-PAGE-unique bands persisted when proteasomes were 
extracted away from chromatin and nuclear architecture prior to exposure to CTAB (Figure1D) 
and, in the case of yeast S. cerevisiae, nuclear and cytosolic proteasome subunits migrated 
identically on CTAB-PAGE (below, Figure S4C). 
 
Additional validation that CTAB-PAGE-unique bands corresponded to true protein species 
came from identifying experimental conditions under which also SDS-PAGE could visualise the 
CTAB-PAGE-unique bands, thus uncoupling visualisation of protein species from use of a particular 
PAGE system. While Figure1D’s sub-cellular fractionation experiment still revealed a striking 
discrepancy between the same samples’ SDS-PAGE and CTAB-PAGE patterns, further purification 
steps led to convergence of proteasome subunit pattern on both PAGE systems. Importantly, with 
increased purification, the SDS-PAGE pattern started to resemble the CTAB-PAGE pattern, rather 
than the other way around (Figure1E, 1F). Thus, on SDS-PAGE, nuclear proteasome subunits also 
migrated as collections of multiple species, on condition that these proteasomes were sufficiently 
purified. Briefly, proteasomes were captured from primary human leukocytes using a resin-
immobilised ubiquitin-like (Ubl) domain of hPLIC2/Ubiquilin2[10, 13-14], then  further purified 
using FPLC size-exclusion chromatography (Figure1E). CTAB-PAGE analysis of purified nuclear 
proteasomes showed extensive modification of the Regulatory Particle (RP) subunits Rpn12 and 
Rpt2, and the 5i Core Particle (CP) subunit, as before; by contrast, the CP subunit 7 migrated as 
a single band (see also Figure2C,2D). Surprisingly, unlike in the experiments described above, 
analysis of purified nuclear proteasomes by SDS-PAGE gave virtually identical results to those seen 
with CTAB-PAGE (Figure1E). One interpretation why SDS-PAGE -with increasing sample 
purification- starts to yield CTAB-PAGE patterns, is that modified nuclear proteasomes interact 
with other components of the nuclear extract and that this interaction prevents SDS-PAGE from 
visualising proteasomes. Consistent with this interpretation, when analysing samples taken over 
the course of a single purification procedure, modified proteasomes were only visible on SDS-
PAGE in samples taken after the Ubl-capturing step (Figure1F), indicating that sample complexity is 
‘masked’ in unpurified lysate or extract mixtures. Interestingly, in Figure 1F, the Ubl domain [10, 
13] did not capture unmodified Rpt2 from the cytoplasmic extract; we found this to be the result 
of the particular construct [10-11] and buffer conditions used (Figure S2). In sum, CTAB-PAGE 
detected human proteasomes that are located in a distinct sub-cellular location, most likely in the 
nucleus (although a tightly-bound cytosolic or cytoskeletal location could not formally be 
excluded, and relative distribution of proteasomes between fractions may depend to some extent 
on fractionation procedure), and that carry constitutive modifications which are largely 
incompatible with SDS-PAGE analysis. 
 
In order to understand why CTAB- but not SDS-PAGE visualised proteins modified in this 
manner, we sought to identify the nature of the posttranslational modification. We used a GST-
Ubl [11] construct to capture proteasomes from either cytoplasmic or subsequent nuclear extract 
(Figure S2), and compared these by two-dimensional isoelectric focusing (IEF)/SDS-PAGE. The 
posttranslational modification substantially changed focusing of proteasomal subunits, even in a 
wide-range pH3-10 gradient (Figure 2A, S3). The modification imparted a complex focusing 
phenotype, including (1) a ‘striated’ rather than punctuate focusing pattern (even in a narrow pH 
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range, Figure 2B, and with steady-state focusing achieved), and (2) diagonal ‘slanting’ towards the 
acidic pole (figure 2B). The pronounced effects of the posttranslational modification on the pI of 
proteasomal subunits strongly suggests it carries charge (and, in the case of the population 
slanting towards the acidic pole, negative charge) [15]. It was not DNA or RNA (Figure2C). We 
found that the modification of nuclear proteasomes shared several characteristics with, but also is 
distinct from, classical ADP-ribose chains (poly(ADP-ribosyl)–PAR–chains)[16-17]. PAR is a nuclear 
modification of high negative charge, which could explain relative incompatibility with (negatively-
charged) SDS-PAGE. Characteristics shared with PAR include: (1) Sensitivity to the PAR hydrolytic 
enzymes PARG, ARH1, ARH2 and ARH3. Incubation with these enzymes, alone or in combination, 
altered the Western blot patterns of several proteasome subunits (Figure2D, 2E). Most of the 
changes reflected activity of PARG, which hydrolyses ribose–ribose linkages between coupled 
ADP-ribose units in PAR chains (Figure2D). Note that, even though we used standard SDS-PAGE 
rather than CTAB-PAGE (as was possible with purified nuclear proteasomes as substrate), PAR-
hydrolysing enzymes had unusual effects on migration of proteasome subunits. These include 
apparent upward migration and increased signal intensity, in part due to PARG-facilitated entry of 
modified proteasome subunits into the SDS-PAGE gel (Figure1F). A direct comparison on SDS-PAGE 
of cytosolic versus (purified) nuclear Rpt2 showed that nuclear Rpt2 migrated with an apparent 
molecular weight range below that of unmodified, cytosolic Rpt2, as may be expected from a 
highly negatively-charged protein modification (Figure1F,2B). (2) Sensitivity to venom 
phosphodiesteraseI (PDE1). PDE1 hydrolyses pyrophosphate bonds of ADP-ribose units in PAR, 
and also changed Rpt2 pattern (Figure2F)[18]. (3) -PAR antibodies immunoprecipitated 
proteasomal antigens and, vice versa, proteasome antibodies immunoprecipitated PAR-reactive 
antigens (FigureS4B). We found that an alternative approach, using biotin-NAD+ for metabolic 
labelling, was not feasible, because living cells did not take up biotin-NAD+ nor could we use 
digitonin-permeabilised cells for our constitutively-present modifications. (4) Yeast proteasomes, 
which lack PAR[19], were unmodified on CTAB-PAGE (FigureS4C). However, the modification of 
human nuclear proteasomes also differs from PAR in several respects: (1) Complete resolution of 
modified nuclear proteasomes into single subunit bands using PAR enzymes was never achieved 
(FigureS4A), even when combined and under a wide variety of experimental conditions. (2) The 
nuclear proteasome modification is constitutively present, whereas standard PAR chains on 
substrates are generally transient, short-lived and synthesised in response to stress at sites of e.g. 
DNA damage[16-17]. Interestingly, the constitutive modification of nuclear proteasomes we 
report here expands on what is already known, namely that standard PAR transiently activates 
nuclear proteasomes to degrade oxidatively damaged histones[8, 17, 20] and regulates 
proteasome assembly in the nucleus via modification of assembly factor PI31[21]. Because 
PDE1/PAR enzyme treatment was only partially effective against the proteasome modification 
(FigureS4A), it has not yet been possible, despite various attempts, to obtain a mass spectrometry 
signature. 
 
Finally, we identified a physiological process which induces changes in CTAB-PAGE 
detectable proteasome modifications. It has been reported that, during apoptosis, activated 
caspases cut once in each of three proteasome subunits. These cleavage events were visualised 
with SDS-PAGE[22-23]. However, we now report, changes to proteasome structure during 
apoptosis are far more dramatic: CTAB-PAGE-unique subunit species of multiple proteasome 
subunits changed dramatically during apoptosis, as observed when treating cells with a lethal dose 
of Bortezomib versus control- or sub-IC50-treated cells (Figure 3A). The same was observed when 
using apoptosis-inducing compounds which are not proteasome inhibitors (Figure 3C, S6A), or 
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proteasome inhibitors other than Bortezomib (Figure S5). Most, but not all, of these changes were 
caspase-dependent, because caspase inhibitors prevented many, though not all, of these changes 
(Figures 3B). Interestingly, by comparing eight human cell lines on CTAB-PAGE, we found that 
proteasome modification patterns can vary to some extent (Figure S6B). We are currently studying 
how this modification affects proteasome function. 
 
In sum, we found that nuclear proteasome subunits carry a posttranslational modification 
which makes those subunits invisible to SDS-PAGE. We identified an alternative system that 
overcomes this problem (CTAB-PAGE), and gained insight into the nature of the modification 
leading to a possible explanation for observed PAGE compatibilities. Finally, we identified the first 
example of specific biology involving CTAB-PAGE detectable protein modifications.  
 
Even though the constitutive modifications of nuclear proteasomes differ from classical 
PAR chains, their sharing of some characteristics suggests a possible function for these 
modifications in proteasome biology. Nuclear proteasomes are known to have a variety of nuclear 
functions [24-28]; they must interact with chromatin, DNA and other nuclear components, but 
little is known about how this is accomplished. In general, when PAR chains are present, they 
recruit e.g. PAR-binding repair proteins to DNA and chromosomes [16-17]. In analogy, we 
hypothesise that proteins in nuclear processes capture the (constitutive) CTAB-PAGE-detectable 
modifications on nuclear proteasomes, thereby recruiting proteasome function to e.g. gene 
expression, even under non-stress conditions. 
 
Our identification of an SDS-PAGE-incompatible protein modification may also explain the 
difficulty in resolving the controversy as to whether RNA species, which early studies suggested 
are associated with proteasomes (then called prosomes)[29], are bona fide components of 
proteasomes [30]. These modifications may account for the reported RNP-like density of 
prosomes/proteasomes, and our finding that SDS-PAGE fails to detect modified proteasomal 
subunits may explain the difficulty in resolving the controversy. Our data suggest that CTAB-PAGE 
should be used routinely in nuclear biology to ascertain whether or not a protein of interest is 
similarly modified. 
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6.1 Figure Legends 
 
Figure 1. A proteasome modification that correlates with subcellular localization. 
 (A) Lysate from KMS12-BM myeloma cells was split and run on SDS and CTAB PAGE systems, 
before being blotted for proteasome subunits. Red brackets indicate CTAB-PAGE unique signal. 
Note that CTAB-PAGE is not inherently prone to smearing: not all proteins we tested migrated as a 
smear (e.g. LaminB2, Figure 1A; Ini1, Rpt3, Figure 1D), and lanes with a CTAB-PAGE-unique smear 
also contained sharply focused bands. (B) NCI-H929 myeloma cells were subjected to subcellular 
fractionation, and fractions were analysed by Western blotting against proteasome subunits using 
CTAB-PAGE. Red brackets indicate CTAB-PAGE unique signal. (C) Presence of divalent cations in 
fractionation buffer affects CTAB-PAGE pattern. NCI-H929 myeloma cells were fractionated using a 
cytosol extraction buffer containing either MgCl2 or EDTA. Fractions were kept on ice or incubated 
at 37oC for one hour, after which they were analysed using CTAB-PAGE and Western blotting with 
an -Rpn12/S14 proteasome subunit antibody. (D) Cell fractionation of NCI-H929 cells was 
extended with a nuclear extraction step. All fractions were split and subjected to CTAB-PAGE and 
SDS-PAGE, and analysed by Western blotting against proteasome subunits. P = Pellet remaining 
after nuclear extraction, C = cytosolic extract, NE = nuclear extract. Notice that although the same 
protein was loaded on both systems, SDS-PAGE doesn’t display all of the species observed in 
CTAB-PAGE. The fractionation protocol (Materials and Methods, section 2.1.3) normalizes for cell 
number: lanes contain the amount of protein extracted or remaining in pellet per equal number of 
cells. In addition, by employing a very efficient stripping procedure [7], the same membrane is 
used for all antibodies, thus eliminating pipetting variation between panels. (E) Nuclear human 
proteasomes were affinity-captured from nuclear extract with a ubiquitin-like proteasome binding 
domain (Ubl-His6), released, and subjected to Superose6 FPLC fractionation. FPLC fractions were 
analysed on both CTAB-PAGE and SDS-PAGE by Western blotting against proteasome subunits. 
Arrows indicate Blue Dextran FPLC marker band. (F) Protein samples were taken from different 
stages of a large-scale nuclear human proteasome purification experiment, and immunoblotted 
with an -Rpt2 proteasome antibody. Unmodified Rpt2 is indicated by an arrow, modified nuclear 
Rpt2 species are indicated with a red bracket. 
 
Figure 2. The constitutive modification of proteasomes shares several characteristics with –but 
is distinct from– poly(ADP)-ribose. 
(A) Proteasomes were captured, using GST-Ubl (see also Figure S2), from both cytoplasmic extract 
and subsequent nuclear extract of myeloma OPM2 cells. The two samples were compared on two-
dimensional isoelectric focusing/SDS-PAGE with an -Rpt2 antibody. The red brackets indicate 
where nucleus-extracted, modified Rpt2 focuses in a pH 3-10 linear gradient. Care was taken to 
ensure that the isoelectric focusing was run to completion and that steady-state positions were 
reached. * indicates nonspecific signal due to the presence of a large amount of GST-Ubl (see 
corresponding PonceauS staining in Figure S3A). (B) Experiment as in (A), but this time samples 
were analyzed on a narrow-range pH 4-7 gradient. A longer exposure of the left part of the gel is 
shown underneath to highlight the ‘striated’ focusing phenotype. (C) Nuclear proteasomes were 
captured with Ubl-His6 and further purified by FPLC, as in Figure 1E. Combined proteasome FPLC 
fractions 13-18 were incubated with nucleotide modification enzymes Micrococcal Nuclease, 
RNaseA/T1 mixture, RNAse1 and RNaseH. Samples were run on SDS-PAGE, and analysed by 
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Western blot using an -Rpt2/S4 proteasomal subunit antibody. (D) Pooled FPLC fractions 12-19 
were incubated with combinations of PAR hydrolysing enzymes PARG, ARH1 and ARH3. 
Subsequently, samples were analysed by SDS-PAGE and Western blotting using several antibodies 
against proteasomal subunits. PAR enzyme-dependent changes in subunit pattern were observed 
for Rpn12, 7 and Rpt2. Prior to re-probing, the membrane was checked after stripping [7] and 
found to be void of signal. (E) The orphan PAR enzyme ARH2, for which no substrate is known as 
yet, does not affect the migration behaviour of the 7 proteasome subunit. Two isoforms of ARH2 
were cloned and tested, neither of which had activity; shown here is ARH-2.2. (F) FPLC fractions 
were incubated with phospodiesterase 1 (PDE1), ARH3 and PARG. Samples were run on SDS-PAGE, 
and analysed by western Blot using an -Rpt2/S4 proteasomal subunit antibodies. 
 
Figure 3. The constitutive modification of proteasomes changes in response to a physiological 
stimulus. 
(A) Western blot analysis of the effects of a Bortezomib concentration range on the CTAB-PAGE 
patterns of several proteasome subunits. NCI-H929 myeloma cells were treated with the indicated 
Bortezomib concentrations for 24 hours, after which total cell lysate was analysed by CTAB-PAGE 
and Western Blot. (Asterisk denotes IC50 value for the NCI-H929 cell line used). The bottom panel 
shows that Bortezomib between 1 and 10 nM induces apoptosis in these cells, as determined by 
AnnexinV-7AAD staining. (B) Western blot analysis of the effects of Bortezomib (20 nM) and a 
caspase inhibitor cocktail on the CTAB-PAGE pattern of proteasome subunits. Indicated with red 
and black arrows are Bortezomib-induced changes in CTAB-PAGE pattern which are caspase-
independent and caspase-mediated, respectively. (C) Myeloma OPM2 cells were treated for 29 hrs 
with Bortezomib (250 nM), doxorubicin (10 g/ml), cycloheximide (500 g/ml), or vinblastin (10 
g/ml). Cell viability was assessed by AnnexinV/DAPI, and total cell lysate was analyzed by CTAB-
PAGE. 
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Highlights 
 Nuclear proteasomes carry a previously unrecognized posttranslational modification 
 Modified subunits of nuclear proteasomes are not visualized by SDS-PAGE 
 Modified subunits of nuclear proteasomes can be observed with CTAB-PAGE 
 Modification shares characteristics with, but also is distinct from, polyADP-ribose 
 Modification suggests mechanism how proteasomes may execute their nuclear functions 
